30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Adult vaccinations, particularly against herpes zoster, influenza, pneumococcus and Tdap, are associated with a lower risk of dementia. 5 key findings →
Design: meta-analysis Participants: 104,031,186 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found no significant association for exposure to nitrogen oxides (five studies, n=241 409, pooled adjusted HR per 10 μg/m 3 increase, 1·05 [0·97-1·13]; I 2 =44%), PM 10 (four studies, n=246 440, pooled adjusted HR per 15 μg/m 3 increase, 1·52 [0·80-2·87]; I 2 =82%), or annual ozone (four studies, n=419 972, pooled adjusted HR per 45 μg/m 3 increase, 0·82 [0·35-1·92]; I 2 =69%), with moderate to considerable heterogeneity between studies in these pooled analyses. 5 key findings →
Design: meta-analysis Participants: 24,030,527 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 7731 participants were included in analysis of risk factors measured at age 45 to 54 years (4494 female [58%]; 2207 Black [29%]; 5524 White [71%]), 12 274 contributed to analysis of risk factors measured at age 55 to 64 years (6698 female [55%]; 2886 Black [24%]; 9388 White [76%]), and 6787 contributed to analysis of risk factors measured at age 65 to 74 years (3764 female [56%], 1375 Black [20%]; 5412 White [80%]). 3 key findings →
Design: cohort Participants: 12,274 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Levels of plasma p-tau217 increased significantly in Aβ+ participants before showing significant deceleration (χ2 = 21.7; P Conclusions and relevance This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression. 2 key findings →
Design: cohort Participants: 1,707 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
CKD was associated with increased p-tau217 concentrations when measuring p-tau217 by ALZpath and C 2 N methodologies, but the effect was mitigated by the use of %p-tau217. 5 key findings →
Design: cross-sectional Participants: 202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MPF (%WC, −2.06 (95% confidence interval (CI), −2.99, −1.13) and UPF (%WC, −1.05 (95% CI, −1.98, −0.13)) resulted in weight loss, with significantly greater %WC on MPF (Δ%WC, −1.01 (95% CI, −1.87, −0.14), P = 0.024; Cohen’s d , −0.48 (95% CI, −0.91, −0.06)). 2 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This review included 24 studies involving 2979 participants (1717 with dysphagia and 1262 controls). 5 key findings →
Design: meta-analysis Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, 2,279 dementia-free participants with available blood samples were included (median age 72 (interquartile range, 61-81) years; 62% female). 4 key findings →
Design: cohort Participants: 2,279 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Between April 30, 2020, and May 9, 2022, we randomly allocated 204 participants (109 [53%] women and 95 [47%] men) to the intervention group and 98 (60 [61%] women and 38 [39%] men) to the control group. 218 (72%) participants at 6 months and 178 (59%) at 12 months provided cost data. 2 key findings →
Design: RCT Participants: 302 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In Alzheimer's disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. 3 key findings →
Design: cohort Participants: 609 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included. 3 key findings →
Design: cross-sectional Participants: 838 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher tau levels are associated with the fastest decline in everyday functioning in the presence of elevated amyloid, and those accumulating more tau show a faster decline in everyday functioning. 3 key findings →
Design: randomized controlled trial Participants: 434 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In 135 older adults (mean age = 69.3 years; women = 61.5%), no associations were found within AD-signature regions (all p > 0.25). 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 716 individuals were included in the analysis: 413 cognitively unimpaired (CU) participants (58.6% female; mean age = 70.6 years, SD = 7.9) and 303 cognitively impaired (CI) participants (54.7% female; mean age = 73.2 years, SD = 7.4). 5 key findings →
Design: longitudinal study Participants: 716 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Two regions achieved genome-wide significance with TDP-43: apolipoprotein E (APOE) and TMEM106B. Three loci reached genome-wide significance with HS: APOE, TMEM106B, and granulin precursor (GRN). 5 key findings →
Design: meta-analysis Participants: 9,509 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The global mortality of ADRD among adults aged ≥65 years increased by 115%, from 6.5 (95% UI 1.5-18) per 100,000 population in 1991 to 14 (95% UI 3.5-37) per 100,000 population in 2021, with an Average Annual Percentage Change (AAPC) of 1.10% (95%CI 0.45%-1.76%). 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The trial occurred during the COVID-19 pandemic. 5 key findings →
Design: randomized controlled trial Participants: 106 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by amyloid-beta (Aβ) accumulation and neuroinflammation. 4 key findings →
Design: clinical trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
APPLE-Tree is an accessible intervention associated with small improvements in cognition, although these results were not statistically significant. 1 key finding →
Design: RCT Participants: 746 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
In this systematic review and meta-analysis, estimates indicate that FTD is comparable in frequency to dementia with Lewy bodies and occurs at higher rates than progressive supranuclear palsy, corticobasal syndrome, and amyotrophic lateral sclerosis. 5 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 486 older adults who provided consent, 375 (with rMDD, MCI, or both) received at least 1 intervention session (mean [SD] age, 72.2 [6.4] years; 232 women [62%] and 143 men [38%]). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. 2 key findings →
Design: cohort study Participants: 1,135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Understanding the neuropathological effects of amyloid β (Aβ)-targeting therapies and amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease is critical for optimising treatment efficacy and patient outcomes. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings provide robust evidence supporting the protective effect of the Mediterranean diet against stroke. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →